Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSP90AA1 | P07900 | 18/20 | 0.78 |
| ▸ | HSP90AB1 | P08238 | 8/20 | 0.78 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.78 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.56 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15160486 | 1.00 | HSP90AA1 (0.78) | HSP90AA1HSP90AB1PDGFRAALDH1A1ERBB2 | |
| SCHEMBL14748322 | 0.92 | HSP90AA1 (0.65) | HSP90AA1HSP90AB1PDGFRAALDH1A1ERBB2 | |
| Retaspimycin SCHEMBL13204564 | 0.88 | HSP90AA1 (0.99) | HSP90AA1HSP90AB1PDGFRAALDH1A1ERBB2 | |
| Retaspimycin SCHEMBL12446217 | 0.88 | HSP90AA1 (0.99) | HSP90AA1HSP90AB1PDGFRAALDH1A1ERBB2 | |
| Retaspimycin SCHEMBL13199456 | 0.88 | HSP90AA1 (0.99) | HSP90AA1HSP90AB1PDGFRAALDH1A1ERBB2 | |
| Retaspimycin SCHEMBL13199500 | 0.88 | HSP90AA1 (0.99) | HSP90AA1HSP90AB1PDGFRAALDH1A1ERBB2 | |
| Retaspimycin SCHEMBL254016 | 0.88 | HSP90AA1 (0.99) | HSP90AA1HSP90AB1PDGFRAALDH1A1ERBB2 | |
| Retaspimycin SCHEMBL254489 | 0.88 | HSP90AA1 (0.99) | HSP90AA1HSP90AB1PDGFRAALDH1A1ERBB2 | |
| Retaspimycin SCHEMBL22496014 | 0.88 | HSP90AA1 (0.99) | HSP90AA1HSP90AB1PDGFRAALDH1A1ERBB2 | |
| Retaspimycin SCHEMBL14748340 | 0.88 | HSP90AA1 (0.99) | HSP90AA1HSP90AB1PDGFRAALDH1A1ERBB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120108563-A1 | Methods Of Treating Liposarcoma | INFINITY PHARMACEUTICALS, INC. (US) | 2012-05-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120108563-A1 | Methods Of Treating Liposarcoma | HSP90AB1, HSP90AA1, HSP90B1 | HSP90AA1 2/4885HSP90AB1 1/4885PDGFRA 2343/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.